Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

BIOTECH INNOVATION ApS

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.3% 1.3%   Bankruptcy risk   9.1% 4.7% 5.5% 5.3% 8.5% 6.8% 7.2% 7.1%   Credit score (0-100)   29 46 41 41 28 34 33 34   Credit rating   BB BBB BBB BBB BB BBB BBB BBB   Credit limit (kDKK)   -0.0 0.0 0.0 0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,136 2,461 1,813 1,285 640 882 0.0 0.0   EBITDA   -379 1,008 296 -224 -821 -419 0.0 0.0   EBIT   -423 977 266 -236 -848 -424 0.0 0.0   Pre-tax profit (PTP)   -492.8 902.9 188.4 -315.7 -934.3 -506.6 0.0 0.0   Net earnings   -385.4 703.1 146.5 -246.7 -871.4 -458.9 0.0 0.0   Pre-tax profit without non-rec. items   -493 903 188 -316 -934 -507 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   22.7 17.9 13.2 10.5 10.0 10.0 0.0 0.0   Shareholders equity total   -1,080 -377 -231 -477 -1,349 -1,808 -2,016 -2,016   Interest-bearing liabilities   1,858 1,562 1,822 2,054 2,148 2,275 2,016 2,016   Balance sheet total (assets)   1,270 1,944 2,447 1,931 1,035 706 0.0 0.0   Net Debt   1,557 478 748 1,232 1,944 2,270 2,016 2,016     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,136 2,461 1,813 1,285 640 882 0.0 0.0   Gross profit growth   -33.7% 116.7% -26.3% -29.1% -50.2% 37.8% -100.0% 0.0%   Employees   3 3 3 3 2 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% -33.3% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,270 1,944 2,447 1,931 1,035 706 0 0   Balance sheet change%   -2.2% 53.1% 25.9% -21.1% -46.4% -31.8% -100.0% 0.0%   Added value   -379.4 1,008.0 296.3 -224.0 -836.4 -418.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -50 -36 -35 -14 -28 -6 -10 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 1.0 2.0 -1.0 -2.0 -3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -37.2% 39.7% 14.7% -18.3% -132.5% -48.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -19.5% 41.8% 10.6% -9.3% -35.4% -17.2% 0.0% 0.0%   ROI %   -23.9% 57.1% 15.5% -12.0% -40.4% -19.0% 0.0% 0.0%   ROE %   -30.0% 43.8% 6.7% -11.3% -58.8% -52.7% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -46.0% -16.2% -8.6% -19.8% -56.6% -71.9% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -410.5% 47.4% 252.3% -549.7% -236.9% -542.4% 0.0% 0.0%   Gearing %   -172.0% -414.3% -790.3% -430.3% -159.3% -125.8% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   4.0% 4.3% 4.6% 4.1% 4.1% 3.9% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.2 0.5 0.7 0.5 0.2 0.1 0.0 0.0   Current Ratio   0.5 0.8 0.9 0.8 0.4 0.3 0.0 0.0   Cash and cash equivalent   301.1 1,084.5 1,074.7 822.5 204.1 4.5 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -1,142.0 -434.1 -232.0 -526.9 -1,412.8 -1,832.6 -1,007.8 -1,007.8   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -126 336 99 -75 -418 -209 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -126 336 99 -75 -410 -209 0 0   EBIT / employee   -141 326 89 -79 -424 -212 0 0   Net earnings / employee   -128 234 49 -82 -436 -229 0 0